Multiple pan-FGFR inhibitors have shown weak efficacy against FGFR4 together with toxicity (hyperphosphatemia and soft tissue mineralization) due to activity against FGFR1 ∼ 3, which indicates a strong need for the discovery of FGFR4-selective inhibitors.27 This evidence concerns the gene FGFR4 and hyperphosphatemia.